Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 531-543

  Bahcelioglu, Meltem ^a   Gozil, Rabet ^a   Take, Gulnur ^a   Elmas, Cigdem ^a   Oktem, Hale ^a   Kadioglu, Dural ^a   Calguner, Engin ^a   Erdogan, Deniz ^a   Sargon, Mustafa F ^b   Yazici, A Canan ^c   Tas, Murat ^d   Bardakci, Yesim ^e   Senol, Selahattin ^a  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

^d Center of Invitro Fertilisation   (Turkey)

^e Zekai Tahir Burak Maternity Teaching Hospital   (Turkey)

Author keywords

ADHD; Brain development; Dopamine D2 receptor occupancy; Psycopharmacology

Indexed keywords

DOPAMINE 2 RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; METHYLPHENIDATE; SODIUM CHLORIDE; CENTRAL STIMULANT AGENT; DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN; CAPILLARY WALL; CEREBELLUM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; NERVE CELL DEGENERATION; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; ULTRASTRUCTURE; AGE; ANIMAL; CAPILLARY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; NERVE DEGENERATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; PINOCYTOSIS; VASCULAR ENDOTHELIUM; VENTRAL TEGMENTUM; WISTAR RAT;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; ASTROCYTES; CAPILLARIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLUM; CEREBRUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOENZYME TECHNIQUES; METHYLPHENIDATE; NERVE DEGENERATION; PINOCYTOSIS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; VENTRAL TEGMENTAL AREA;

EID: 77449085435     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970903176683     Document Type: Article

References (51)

1. Aktas Z, Cansi A, Erdogan D, Take G, Goktas G, Ozdek S, et al. 2009. Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat. Seizure. 18:396-399. doi:10.1016/j.seizure.2009.02.003
2. Amini B, Yang PB, Swann AC, Dafny N. 2004. Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci 114:1063-1084.
3. Anderson CM, Polcari A, Lowen SB, Renshaw PF, Teicher MH. 2002. Effects of methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in boys with ADHD. Am J Psychiatry 159:1322-1328.
4. Andreazza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM, Comim CM, et al. 2007. DNA damage in rats after treatment with methylphenidate. Prog Neuro-Psychopharmacol Biol Psychiatry 31:1282-1288.
5. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, et al. 2001. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231-238.
6. Benes FM. 1998. Brain development, VII. Human brain growth spans decades. Am J Psychiatry 155:1489.
7. Berquin PC, Giedd JN, Jacobsen LK, Hamburger SD, Krain AL, Rapoport JL, et al. 1998. Cerebellum in attention-deficit hyperactivity disorder: a morphometric MRI study. Neurology 50:1087-1093.
8. Blanchard DC, Shepherd JK, De Padua Carobrez A, Blanchard RJ. 1991. Sex effects in defensive behavior: Baseline differences and drug interactions. Neurosci Biobehav Rev 15:461-468
9. Brandon CL, Marinelli M, Baker LK, White FJ. 2001. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25:651-661.
10. Brandon CL, Marinelli M, White FJ. 2003. Adolescent exposure to Methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry 54:1338-1344.
11. Camp DM, Robinson TE. 1988. Susceptibility to sensitisation: II. The influence of gonadal hormones on the enduring changes in brain monamines and behaviour produced by the repeated administration of D-amphetamine or restraint stress. Behav Brain Res 30:69-88.
12. Castellanos FX. 1997. Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr (Philadelphia) 36:381-393.
13. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP, et al. 1996. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53:607-616.
14. Castellanos FX, Giedd JN, Berquin PC, Walter JM, Sharp W, Tran T, et al. 2001. Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58:289-295.
15. Castner SA, Goldman-Rakic PS. 1999. Long-lasting psychotomi-matic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20:10-28.
16. Cavallotti C, Nuti F, Bruzzone P, Mancone M. 2002. Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol 29:412-418 (Pubitemid 34535362)
17. Chase TD, Carrey N, Brown RE, Wilkinson M. 2005. Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Dev Brain Res 156:1-12. (Pubitemid 40603275)
18. Delaney P, Estes M. 1980. Intracranial hemorrhage with amphetamine abuse. Neurology 30:1125-1128.
19. Dinn WM, Robbins NC, Harris CL. 2001. Adult attention-deficit/ hyperactivity disorder: Neuropsychological correlates and clinical presentation. Brain Cogn 46:114-121.
20. Easton N, Steward C, Marshall F, Fone K, Marsden C. 2007. Effects of amphetamine isomers, methylphenidate and atomox-etine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52:405-414
21. Eng LF, DeArmond SJ. 1986. Immunocytochemical studies of astrocytes in normal development and disease. Adv Cell Neurobiol 3:145-171.
22. Feron F, Hendriksen J, van Kroonenburgh M, Blom-Coenjaerts C, Kessels A, Jolles J, et al. 2005. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. Pediatr Neurol 33:179-183.
23. Francis JW, Visger J, Markelonis J, Oh TH. 1995. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phen-yl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol Teratol 17:7-12.
24. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, et al. 1999. Brain development during childhood and adolescence: A longitudinal MRA study. Nat Neurosci 2:861-863.
25. Glaser PE, Surgener SP, Grondin R, Gash CR, Palmer M, Castellanos FX, et al. 2006. Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis? J Neurosci Methods 151:62-67.
26. Harlan RE, Garcia MM. 1998. Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 16:221-267.
27. Ikai Y, Takada M, Shinonaga Y, Mizuno N. 1992. Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience 51:719-728.
28. Ikai Y, Takada M, Mizuno N. 1994. Single neurons in the ventral tegmental area that project to both the cerebral and cerebellar cortical areas by way of axon collaterals. Neuroscience 61:925-934.
29. Krain AL, Castellanos FX. 2006. Brain development and ADHD. Clin Psychol Rev 26:433-444.
30. Kuczenski R, Segal DS. 2002. Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22:7264-7271.
31. Lagace DC, Yee JK, Bolanos CA, Eisch AJ. 2006. Juvenile administration of methylphenidate attenuates adult hippocam-pal neurogenesis. Biol Psychiatry 60:1121-1130.
32. LeBlanc-Duchin D, Taukulis HK. 2004. Behavioral reactivity to a noradrenergic challenge after chronic oral methylphenidate (Ritalin) in rats. Pharmacol Biochem Behav 79:641-649.
33. Lin RC, Polsky K, Matesic DF. 1993. Expression of gamma-aminobutyric acid immunoreactivity in reactive astrocytes after ischemia-induced injury in the adult forebrain. Brain Res 600:1-8.
34. Mague SD, Andersen SL, Carlezon WA, Jr. 2005. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 57:120-125.
35. Meintzschel F, Ziemann U. 2006. Modification of practice-dependent plasticity in human motor cortex by neuromodulators. Cereb Cortex 16:1106-1115.
36. Melchitzky DS, Lewis DA. 2000. Tyrosine hydroxylase-and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular-and laminar-specific dopamine innervation. Neuropsychopharmacology 22:466-472.
37. Mostofsky SH, Reiss AL, Lockhart P, Denckla MB. 1998. Evaluation of cerebellar size in attention-deficit hyperactivity disorder. J Child Neurol 13:434-439.
38. Rothrock JF, Rubenstein R, Lyden PD. 1988. Ischemic stroke associated with methamphetamine inhalation. Neurology 38:589-592.
39. Schenk S, Izenwasser S. 2002. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol Biochem Behav 72:651-657.
40. Schteinschnaider A, Plaghos LL, Garbugino S, Riveros D, Lazarowski A, Intruvini S, et al. 2000. Cerebral arteritis following methylphenidate use. J Child Neurol 15:265-267.
41. Sellings LH, McQuade LE, Clarke PB. 2006. Characterization of dopamine-dependent rewarding and locomotor stimulant effects of intravenously-administered methylphenidate in rats. Neuroscience 141:1457-1468.
42. Stromberg L, Bjorklund H, Dahl D, Jonsson G, Sundstrom E, Olson L. 1986. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull 17:225-236.
43. Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND. 2007. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Behav 87:426-433
44. Torres G, Horowitz JM. 1999. Drugs of abuse and brain gene expression. Psychosom Med 61:630-650.
45. Trugman JM. 1988. Cerebral arteritis and oral methylphenidate. Lancet 12:584-585.
46. Volkow ND, Insel TR. 2003. What are the long-term effects of methylphenidate treatment? Biol Psychiatry 54:1307-1309.
47. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. 2001. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci:R 21:C121.
48. Wooters TE, Dwoskin LP, Bardo MT 2006. Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders. Psycho-pharmacology (Berlin) 188:18-27.
49. Yang PB, Swann AC, Dafny N. 2006a. Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull 71:301-310.
50. Yang PB, Swann AC, Dafny N. 2006b. Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology 51:546-556.
51. Yano M, Steiner H. 2005. Topography of methylphenidate (ritalin)-induced gene regulation in the striatum: differential effects on c-fos, substance P and opioid peptides. Neuropsychopharmacology 30:901-915.